Durable response to afatinib rechallenge in a long‐term survivor of non‐small cell lung cancer harboring EGFR L858R and L747V mutations
Autor: | Mio Kanbe, Noriaki Sunaga, Kenichiro Hara, Hiiru Sawada, Ikuo Wakamatsu, Kentaro Hara, Sohei Muto, Yuri Sawada, Hiroaki Masubuchi, Mari Sato, Yosuke Miura, Hiroaki Tsurumaki, Masakiyo Yatomi, Reiko Sakurai, Yasuhiko Koga, Yoichi Ohtaki, Toshiteru Nagashima, Naoko Okano, Nobuteru Kubo, Toshitaka Maeno, Takeshi Hisada |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2022 |
Předmět: | |
Zdroj: | Thoracic Cancer, Vol 13, Iss 22, Pp 3225-3228 (2022) |
Druh dokumentu: | article |
ISSN: | 1759-7714 1759-7706 |
DOI: | 10.1111/1759-7714.14678 |
Popis: | Abstract Epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors are standard therapeutic agents for non‐small cell lung cancer (NSCLC) patients with major EGFR mutations such as exon 19 deletions and a L858R mutation, whereas treatment strategies for cases with uncommon EGFR mutations remain to be fully established. Here, we report a long‐term (≥20 years from initial diagnosis) NSCLC survivor carrying EGFR L858R and L747V mutations. The patient received gefitinib monotherapy, systemic chemotherapy/chemoimmunotherapy, and local consolidative therapies for oligometastatic lesions, and responded to afatinib rechallenge with a progression‐free survival of 12 months. The current case suggests that afatinib is effective in NSCLC patients with EGFR L858R and L747V mutations and that a therapeutic approach combining appropriately timed systemic therapies with local consolidative therapies for oligometastatic lesions improves long‐term survival. |
Databáze: | Directory of Open Access Journals |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |